Shorter, stronger radiation for prostate cancer: a new hope?

NCT ID NCT04147806

Ongoing Disease control Sponsor: Albert Einstein College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests two ultra-high-dose radiation schedules in 31 men with intermediate-risk prostate cancer. One group gets five high-dose sessions over a week; the other gets a single massive dose. The goal is to see if these shorter treatments are safe and can control the cancer. Participants are followed for at least 5 years to monitor side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (IGRT) with dexamethasone and tamsulosin
What this could lead to: If successful, this could lead to a shorter, more convenient radiation treatment for prostate cancer with fewer side effects.
What could go wrong: This is a very early Phase 1 pilot study with only 31 participants. The high radiation dose may cause unexpected urinary, rectal, or sexual side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Montefiore Medical Center - Moses Campus

The Bronx, New York, 10467-2490, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.